- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - pharmaceuticals
- VENUS REMEDIES - ADCOCK INGRAM (S. Africa)
VENUS REMEDIES vs ADCOCK INGRAM (S. Africa) - Comparison Results
ADCOCK INGRAM (S. Africa)
Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
Financials
 VENUS REMEDIES  ADCOCK INGRAM |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| VENUS REMEDIES Mar-18 |
ADCOCK INGRAM Jun-14 |
VENUS REMEDIES/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 126 | 367 | - | |
| Low | Rs | 61 | 265 | - | |
| Sales per share (Unadj.) | Rs | 301.8 | 109.1 | - | |
| Earnings per share (Unadj.) | Rs | -24.9 | -27.5 | - | |
| Cash flow per share (Unadj.) | Rs | 2.5 | -22.8 | - | |
| Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
| Dividend yield (eoy) | % | 0 | 0 | - | |
| Book value per share (Unadj.) | Rs | 293.3 | 85.7 | - | |
| Shares outstanding (eoy) | m | 12.34 | 168.78 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 0.3 | 2.9 | 10.7% | |
| Avg P/E ratio | x | -3.8 | -11.5 | 32.7% | |
| P/CF ratio (eoy) | x | 36.7 | -13.9 | -265.2% | |
| Price / Book Value ratio | x | 0.3 | 3.7 | 8.6% | |
| Dividend payout | % | 0 | 0 | - | |
| Avg Mkt Cap | Rs m | 1,154 | 53,291 | 2.2% | |
| No. of employees | `000 | 0.9 | 4.3 | 21.5% | |
| Total wages/salary | Rs m | 393 | 3,345 | 11.8% | |
| Avg. sales/employee | Rs Th | 4,026.1 | 4,290.3 | 93.8% | |
| Avg. wages/employee | Rs Th | 425.0 | 779.1 | 54.5% | |
| Avg. net profit/employee | Rs Th | -331.8 | -1,081.1 | 30.7% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 3,724 | 18,418 | 20.2% | |
| Other income | Rs m | 23 | 129 | 17.4% | |
| Total revenues | Rs m | 3,747 | 18,547 | 20.2% | |
| Gross profit | Rs m | 395 | -3,192 | -12.4% | |
| Depreciation | Rs m | 338 | 795 | 42.6% | |
| Interest | Rs m | 354 | 499 | 71.0% | |
| Profit before tax | Rs m | -275 | -4,357 | 6.3% | |
| Minority Interest | Rs m | 0 | -12 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 32 | 272 | 11.6% | |
| Profit after tax | Rs m | -307 | -4,641 | 6.6% | |
| Gross profit margin | % | 10.6 | -17.3 | -61.2% | |
| Effective tax rate | % | -11.5 | -6.2 | 183.7% | |
| Net profit margin | % | -8.2 | -25.2 | 32.7% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 2,638 | 13,490 | 19.6% | |
| Current liabilities | Rs m | 2,305 | 7,590 | 30.4% | |
| Net working cap to sales | % | 8.9 | 32.0 | 27.9% | |
| Current ratio | x | 1.1 | 1.8 | 64.4% | |
| Inventory Days | Days | 135 | 111 | 122.1% | |
| Debtors Days | Days | 46 | 124 | 37.4% | |
| Net fixed assets | Rs m | 4,871 | 7,863 | 61.9% | |
| Share capital | Rs m | 123 | 86 | 144.3% | |
| Net worth | Rs m | 3,619 | 14,456 | 25.0% | |
| Long term debt | Rs m | 1,374 | 5,080 | 27.1% | |
| Total assets | Rs m | 7,509 | 27,309 | 27.5% | |
| Interest coverage | x | 0.2 | -7.7 | -2.9% | |
| Debt to equity ratio | x | 0.4 | 0.4 | 108.1% | |
| Sales to assets ratio | x | 0.5 | 0.7 | 73.5% | |
| Return on assets | % | 0.6 | -15.2 | -4.2% | |
| Return on equity | % | -8.5 | -32.1 | 26.4% | |
| Return on capital | % | 1.6 | -19.8 | -8.0% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 514 | 1,572 | 32.7% | |
| From Investments | Rs m | -123 | -483 | 25.5% | |
| From Financial Activity | Rs m | -387 | 4,611 | -8.4% | |
| Net Cashflow | Rs m | 4 | 5,700 | 0.1% | |
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.06 Rs / ZAR
Compare VENUS REMEDIES With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare VENUS REMEDIES With: UNICHEM LAB PLETHICO PHARMA LUPIN LTD SUN PHARMA DR. DATSONS LABS
|
| |
Today's Market
Sensex Ends 274 Points Lower; IT and Energy Stocks Witness Selling(Closing)
Share markets in India continued to witness selling pressure during closing hours and ended their trading session on a negative note.
Related Views On News
VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)
Aug 20, 2018 | Updated on Aug 20, 2018For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.
VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2% (Quarterly Result Update)
Jun 12, 2018 | Updated on Jun 12, 2018For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
More Views on NewsMost Popular
These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)
Nov 9, 2018All blue chip companies are large caps but all large caps are not blue chips.
5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)
Nov 12, 2018A brand new technology and a stock that could soar with the upcoming 5G rollout.
Why the Realty Sector's Recovery Has Been Delayed(Sector Info)
Nov 15, 2018NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?
This Was a Large Cap. But Was It Safe?(Chart Of The Day)
Nov 9, 2018Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.
Investing In Small Cap Funds? Read This Before You Invest(Outside View)
Nov 19, 2018PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.
More|
| |
VENUS REMEDIES SHARE PRICE
Nov 21, 2018 03:35 PM
TRACK VENUS REMEDIES
- Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON VENUS REMEDIES
VENUS REMEDIES 5-YR ANALYSIS
COMPARE VENUS REMEDIES WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.